ATE141326T1 - Methode zur ortsspezifischen änderung von rna und produktion von dadurch kodierten polypeptiden - Google Patents

Methode zur ortsspezifischen änderung von rna und produktion von dadurch kodierten polypeptiden

Info

Publication number: ATE141326T1
Authority: AT; Austria
Prior art keywords: site; rna molecule; rna; production; polypeptides encoded
Prior art date: 1990-02-15

Application number

AT91904770T

Other languages

English (en)

Inventor

Thoru Pederson

Sudhir Agrawal

Sandra Mayrand

Paul C Zamecnik

Original Assignee

Worcester Found Ex Biology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-02-15

Filing date

1991-02-13

Publication date

1996-08-15

1991-02-13 Application filed by Worcester Found Ex Biology filed Critical Worcester Found Ex Biology

1996-08-15 Application granted granted Critical

1996-08-15 Publication of ATE141326T1 publication Critical patent/ATE141326T1/de

Links

238000000034 method Methods 0.000 title abstract 6
229920001184 polypeptide Polymers 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
238000012986 modification Methods 0.000 title 1
230000004048 modification Effects 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000004075 alteration Effects 0.000 abstract 1
238000003776 cleavage reaction Methods 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000007017 scission Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8222—Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation
- C12N15/823—Reproductive tissue-specific promoters
- C12N15/8233—Female-specific, e.g. pistil, ovule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8222—Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation
- C12N15/823—Reproductive tissue-specific promoters
- C12N15/8235—Fruit-specific
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Cell Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Studio Devices (AREA)
Near-Field Transmission Systems (AREA)

AT91904770T 1990-02-15 1991-02-13 Methode zur ortsspezifischen änderung von rna und produktion von dadurch kodierten polypeptiden ATE141326T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/480,269 US5149797A (en)	1990-02-15	1990-02-15	Method of site-specific alteration of rna and production of encoded polypeptides

Publications (1)

Publication Number	Publication Date
ATE141326T1 true ATE141326T1 (de)	1996-08-15

Family

ID=23907315

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91904770T ATE141326T1 (de)	1990-02-15	1991-02-13	Methode zur ortsspezifischen änderung von rna und produktion von dadurch kodierten polypeptiden

Country Status (10)

Country	Link
US (3)	US5149797A (de)
EP (1)	EP0515511B1 (de)
JP (1)	JPH05506355A (de)
AT (1)	ATE141326T1 (de)
CA (1)	CA2076037A1 (de)
DE (1)	DE69121391T2 (de)
DK (1)	DK0515511T3 (de)
ES (1)	ES2090314T3 (de)
GR (1)	GR3021278T3 (de)
WO (1)	WO1991012323A1 (de)

Families Citing this family (592)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6399754B1 (en) *	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US5955589A (en) *	1991-12-24	1999-09-21	Isis Pharmaceuticals Inc.	Gapped 2' modified oligonucleotides
US5623065A (en) *	1990-08-13	1997-04-22	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
US5149797A (en) *	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
US5965722A (en) *	1991-05-21	1999-10-12	Isis Pharmaceuticals, Inc.	Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
WO1994008003A1 (en) *	1991-06-14	1994-04-14	Isis Pharmaceuticals, Inc.	ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US20060270624A1 (en) *	1991-12-24	2006-11-30	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
US5700922A (en) *	1991-12-24	1997-12-23	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
JP3131222B2 (ja)	1991-12-24	2001-01-31	アイシス・ファーマシューティカルス・インコーポレーテッド	ギャップを有する２′修飾オリゴヌクレオチド
US6277603B1 (en)	1991-12-24	2001-08-21	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
US5856455A (en) *	1991-12-24	1999-01-05	Isis Pharmaceuticals, Inc.	Gapped 2'-modified oligonucleotides
US6346614B1 (en) *	1992-07-23	2002-02-12	Hybridon, Inc.	Hybrid oligonucleotide phosphorothioates
US5652355A (en) *	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
TW244371B (de) *	1992-07-23	1995-04-01	Tri Clover Inc
US5523389A (en) *	1992-09-29	1996-06-04	Isis Pharmaceuticals, Inc.	Inhibitors of human immunodeficiency virus
WO1994013793A1 (en) *	1992-12-04	1994-06-23	Apollon, Inc.	Compounds and methods for the treatment of leukemias
NZ263985A (en) *	1993-03-31	1997-07-27	Hybridon Inc	Oligonucleotide complementary to an essential amino acid sequence of influenza virus
DE69435005T2 (de) *	1993-05-11	2008-04-17	The University Of North Carolina At Chapel Hill	Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung
US6410322B1 (en) *	1993-07-27	2002-06-25	Hybridon Inc	Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US6605708B1 (en)	1993-07-28	2003-08-12	Hybridon, Inc.	Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
ATE247128T1 (de)	1993-09-03	2003-08-15	Isis Pharmaceuticals Inc	Aminoderivatisierte nukleoside und oligonukleoside
WO1995009236A1 (en) *	1993-09-28	1995-04-06	The General Hospital Corporation	USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE β/A4 AMYLOID-INDUCED MORPHOLOGY
IL111660A (en) *	1993-11-16	2005-05-17	Genta Inc	Oligonucleoside compounds for effecting rnaseh-mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them
WO1995014106A2 (en) *	1993-11-17	1995-05-26	Id Biomedical Corporation	Cycling probe cleavage detection of nucleic acid sequences
US5550047A (en) *	1994-02-18	1996-08-27	University Of Massachusetts	Oligonucleotides with anti-Epstein-Barr virus activity
US5801235A (en) *	1994-05-25	1998-09-01	Hybridon, Inc.	Oligonucleotides with anti-cytomegalovirus activity
US5691316A (en) *	1994-06-01	1997-11-25	Hybridon, Inc.	Cyclodextrin cellular delivery system for oligonucleotides
US6608035B1 (en)	1994-10-25	2003-08-19	Hybridon, Inc.	Method of down-regulating gene expression
US5591721A (en) *	1994-10-25	1997-01-07	Hybridon, Inc.	Method of down-regulating gene expression
US6645943B1 (en)	1994-10-25	2003-11-11	Hybridon, Inc.	Method of down-regulating gene expression
US5750341A (en) *	1995-04-17	1998-05-12	Lynx Therapeutics, Inc.	DNA sequencing by parallel oligonucleotide extensions
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US20030055240A1 (en) *	1995-06-06	2003-03-20	Roberts Peter C.	HPV specific oligonucleotides
US6509149B2 (en) *	1995-06-06	2003-01-21	Hybridon, Inc.	HPV-specific oligonucleotides
US6624293B1 (en)	1995-08-17	2003-09-23	Hybridon, Inc.	Modified protein kinase A-specific oligonucleotides and methods of their use
US7074768B2 (en)	1995-08-17	2006-07-11	Idera Pharmaceuticals, Inc.	Modified protein kinase A-specific oligonucleotides and methods of their use
US5652356A (en) *	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
NZ331217A (en)	1996-02-14	2000-02-28	Novartis Ag	Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US20040266706A1 (en) *	2002-11-05	2004-12-30	Muthiah Manoharan	Cross-linked oligomeric compounds and their use in gene modulation
US20040161777A1 (en) *	1996-06-06	2004-08-19	Baker Brenda F.	Modified oligonucleotides for use in RNA interference
US9096636B2 (en) *	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
US5886165A (en) *	1996-09-24	1999-03-23	Hybridon, Inc.	Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
CA2294988C (en)	1997-07-01	2015-11-24	Isis Pharmaceuticals Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6013786A (en) *	1997-08-22	2000-01-11	Hybridon, Inc.	MDM2-specific antisense oligonucleotides
US20030036516A1 (en) *	1997-09-10	2003-02-20	Sudhir Agrawal	Method for using oligonucleotides having modified cpg dinucleotides
US6306831B1 (en)	1997-09-12	2001-10-23	Qik Technologies, Inc.	Transplacental delivery of oligonucleotides
WO2000018885A1 (en)	1998-09-29	2000-04-06	Gamida Cell Ltd.	Methods of controlling proliferation and differentiation of stem and progenitor cells
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
WO1999060012A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals, Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
WO1999060167A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
US5962672A (en) *	1998-09-18	1999-10-05	Isis Pharmaceuticals Inc.	Antisense modulation of RhoB expression
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US5959097A (en) *	1998-11-20	1999-09-28	Isis Pharmaceuticals, Inc.	Antisense modulation of MEK2 expression
US5977341A (en) *	1998-11-20	1999-11-02	Isis Pharmaceuticals Inc.	Antisense modulation of inhibitor-kappa B kinase-beta expression
US5962673A (en) *	1998-11-20	1999-10-05	Isis Pharmaceuticals Inc.	Antisense modulation of inhibitor-kappa B kinase-alpha expression
US5981732A (en) *	1998-12-04	1999-11-09	Isis Pharmaceuticals Inc.	Antisense modulation of G-alpha-13 expression
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
CA2364305A1 (en)	1999-03-31	2000-10-05	The University Of North Carolina At Chapel Hill	Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6013788A (en) *	1999-04-09	2000-01-11	Isis Pharmaceuticals Inc.	Antisense modulation of Smad3 expression
US6046321A (en) *	1999-04-09	2000-04-04	Isis Pharmaceuticals Inc.	Antisense modulation of G-alpha-i1 expression
US20030078216A1 (en) *	1999-05-03	2003-04-24	Macleod A. Robert	Inhibition of histone deactylase
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US7101989B1 (en)	1999-07-09	2006-09-05	University Of North Carolina At Chapel Hill	DsrA protein and polynucleotides encoding the same
US6677445B1 (en)	1999-08-27	2004-01-13	Chiron Corporation	Chimeric antisense oligonucleotides and cell transfecting formulations thereof
US20010011126A1 (en) *	1999-09-10	2001-08-02	Bock Elisabeth Marianne	Neurogenic compositions and methods
US7668658B2 (en)	1999-10-13	2010-02-23	Sequenom, Inc.	Methods for generating databases and databases for identifying polymorphic genetic markers
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
EP2093292A2 (de)	2000-03-24	2009-08-26	Methylgene, Inc.	Spezifische Hemmung von Histon-deacylasen Isoformen
WO2001074346A2 (en) *	2000-04-03	2001-10-11	Hybridon, Inc.	Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US6764826B2 (en) *	2000-06-08	2004-07-20	Board Of Regents, The University Of Texas System	Inhibitors of C-reactive protein induced inflammation
US6958214B2 (en) *	2000-07-10	2005-10-25	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US6380377B1 (en) *	2000-07-14	2002-04-30	Applied Gene Technologies, Inc.	Nucleic acid hairpin probes and uses thereof
US6596490B2 (en) *	2000-07-14	2003-07-22	Applied Gene Technologies, Inc.	Nucleic acid hairpin probes and uses thereof
US20030148970A1 (en) *	2001-01-12	2003-08-07	Besterman Jeffrey M.	Methods for specifically inhibiting histone deacetylase-4
US20030152557A1 (en) *	2001-01-12	2003-08-14	Besterman Jeffrey M.	Methods for inhibiting histone deacetylase-4
WO2002059337A1 (en) *	2001-01-26	2002-08-01	Georgetown University School Of Medicine	Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
WO2002081640A2 (en) *	2001-04-06	2002-10-17	Georgetown University	Gene shinc-1 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en)	2001-04-06	2002-10-21	Georgetown University	Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) *	2001-04-06	2002-10-17	Georgetown University	Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) *	2001-04-06	2002-10-17	Georgetown University	Gene scc-112 and diagnostic and therapeutic uses thereof
US20030083292A1 (en) *	2001-05-11	2003-05-01	Macleod Alan Robert	Inhibitors of DNA methyltransferase isoforms
PT2000545E (pt)	2001-06-20	2011-12-21	Genentech Inc	Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
EP2221376B1 (de)	2001-06-21	2012-11-21	Isis Pharmaceuticals, Inc.	Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
SE0102327D0 (sv)	2001-06-28	2001-06-28	Active Biotech Ab	A novel engineered superantigen for human therapy
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US20040266718A1 (en) *	2001-08-06	2004-12-30	Zuomei Li	Inhibition of specific histone deacetylase isoforms
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US6897220B2 (en) *	2001-09-14	2005-05-24	Methylgene, Inc.	Inhibitors of histone deacetylase
CN101851173A (zh) *	2001-09-14	2010-10-06	梅特希尔基因公司	组蛋白脱乙酰化酶抑制剂
US7868204B2 (en) *	2001-09-14	2011-01-11	Methylgene Inc.	Inhibitors of histone deacetylase
DE60238143D1 (de)	2001-09-18	2010-12-09	Genentech Inc	Zusammensetzungen und verfahren für die diagnose von tumoren
EP1488233A4 (de)	2001-10-09	2006-06-21	Genentech Inc	Neue saure säugerproteine und diese codierende polynukleotide
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
US7276489B2 (en) *	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
AU2002367318B2 (en)	2002-01-02	2007-07-12	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en)	2002-01-25	2003-07-31	Gamida-Cell Ltd.	Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7244565B2 (en) *	2002-04-10	2007-07-17	Georgetown University	Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) *	2002-04-10	2006-11-21	Georgetown University	Gene SHINC-2 and diagnostic and therapeutic uses thereof
JP2005536190A (ja)	2002-04-16	2005-12-02	ジェネンテック・インコーポレーテッド	腫瘍の診断と治療のための組成物と方法
WO2003093296A2 (en)	2002-05-03	2003-11-13	Sequenom, Inc.	Kinase anchor protein muteins, peptides thereof, and related methods
US20030228317A1 (en) *	2002-05-22	2003-12-11	Prafulla Gokhale	Gene BRCC-1 and diagnostic and therapeutic uses thereof
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20050221326A1 (en) *	2002-06-12	2005-10-06	Avi Orr-Urtreger	Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
US20040072770A1 (en) *	2002-07-03	2004-04-15	Besterman Jeffrey M.	Methods for specifically inhibiting histone deacetylase-7 and 8
US20040009483A1 (en) *	2002-07-12	2004-01-15	Ilsley Diane D.	Method of linear mRNA amplification using total RNA
KR20120002613A (ko)	2002-08-12	2012-01-06	제네렉스, 인코포레이티드	폭스바이러스 및 암과 관련된 방법 및 조성물
AU2003263853A1 (en) *	2002-08-16	2004-03-03	Board Of Regents The University Of Texas System	Compositions and methods related to flavivirus envelope protein domain iii antigens
US20050196382A1 (en) *	2002-09-13	2005-09-08	Replicor, Inc.	Antiviral oligonucleotides targeting viral families
BR0314236A (pt) *	2002-09-13	2005-08-09	Replicor Inc	Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
EP2298338B1 (de)	2002-09-16	2012-08-22	Agennix Incorporated	Lactoferrin-Zusammenfassungen und Verfahren zur Behandlung von Hautwunden
US7229976B2 (en)	2002-09-26	2007-06-12	Isis Pharmaceuticals, Inc.	Modulation of forkhead box O1A expression
CA2499880A1 (en) *	2002-09-27	2004-04-08	University Of North Carolina At Chapel Hill	Methods and compositions for modification of splicing of pre-mrna
AU2003273701A1 (en) *	2002-10-17	2004-05-04	Methylgene Inc.	Inhibitors of histone deacetylase
CA2504720C (en)	2002-11-05	2013-12-24	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003291755A1 (en)	2002-11-05	2004-06-07	Isis Pharmaceuticals, Inc.	Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
EP2336318B1 (de)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
SI1569695T1 (sl)	2002-11-13	2013-08-30	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
JP4555089B2 (ja)	2002-11-15	2010-09-29	モーフオテク・インコーポレーテツド	ｉｎｖｉｔｒｏ免疫感作により創製されたハイブリドーマからの抗体の高生産量の生成方法
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
CA2512484A1 (en) *	2003-01-16	2004-05-08	Hybridon, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) *	2003-02-07	2008-04-08	Idera Pharmaceuticals, Inc.	Short immunomodulatory oligonucleotides
NZ541637A (en)	2003-02-11	2008-07-31	Antisense Therapeutics Pty Ltd	Modulation of insulin like growth factor I receptor
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
CA2518475C (en)	2003-03-07	2014-12-23	Alnylam Pharmaceuticals, Inc.	Irna agents comprising asymmetrical modifications
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
EP1611153B1 (de)	2003-04-02	2010-06-16	Board Of Regents, The University Of Texas System	Anti-tumor effekt von bik-mutanten
CA2521464C (en)	2003-04-09	2013-02-05	Alnylam Pharmaceuticals, Inc.	Irna conjugates
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
ES2702942T3 (es)	2003-04-17	2019-03-06	Alnylam Pharmaceuticals Inc	Agentes de ARNi modificados
JP4991288B2 (ja)	2003-04-17	2012-08-01	アルナイラムファーマシューティカルズ，インコーポレイテッド	二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
MXPA05012421A (es) *	2003-05-16	2006-02-22	Hybridon Inc	Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
JP4579911B2 (ja)	2003-06-03	2010-11-10	アイシス・ファーマシューティカルズ・インコーポレイテッド	スルビビン発現の調節
MXPA05013658A (es) *	2003-06-11	2006-03-02	Hybridon Inc	Oligonucleotidos inmunomoduladores estabilizados.
EP1644475A4 (de) *	2003-06-20	2009-06-03	Isis Pharmaceuticals Inc	Doppelstrang-zusammensetzungen mit einem 3'-endo-modifizierten strang zur verwendung bei der genmodulation
MXPA06000619A (es) *	2003-07-15	2006-04-11	Hybridon Inc	Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
EP2256201A3 (de)	2003-09-18	2012-07-04	Isis Pharmaceuticals, Inc.	Modulation der eIF4E expression
CA2538252C (en)	2003-09-18	2014-02-25	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
WO2005030705A1 (en) *	2003-09-24	2005-04-07	Methylgene, Inc.	Inhibitors of histone deacetylase
WO2005038013A1 (en) *	2003-10-07	2005-04-28	Isis Pharmaceuticals, Inc.	Artisense oligonucleotides optimized for kidney targeting
CA2541438C (en)	2003-10-10	2013-11-26	Meditech Research Limited	The modulation of hyaluronan synthesis and degradation in the treatment of disease
CN1910293B (zh)	2003-10-23	2011-04-13	伊洛默格生物科学公司	检测与抗病毒感染性有关的基因oas1中的突变的方法
US20050191653A1 (en) *	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
DK2295073T3 (da)	2003-11-17	2014-07-28	Genentech Inc	Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
US20050120397A1 (en) *	2003-11-24	2005-06-02	Hermann Steller	Compounds and methods for regulation of spermatid differentiation
CA2549173A1 (en)	2003-12-08	2005-07-07	Hybridon, Inc.	Modulation of immunostimulatory properties by small oligonucleotide-based compounds
WO2005062923A2 (en) *	2003-12-24	2005-07-14	Massachusetts Institute Of Technology	Gene targets for enhanced carotenoid production
US7741070B2 (en) *	2003-12-24	2010-06-22	Massachusetts Institute Of Technology	Gene targets for enhanced carotenoid production
US7608699B2 (en) *	2003-12-29	2009-10-27	Rockefeller University	Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
EP1711606A2 (de)	2004-01-20	2006-10-18	Isis Pharmaceuticals, Inc.	Modulation der expression des glucocorticoidrezeptors
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
JP2007523173A (ja) *	2004-02-20	2007-08-16	イデラファーマシューティカルズインコーポレイテッド	修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en) *	2004-03-15	2014-07-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of RNA by RNase H
US7253204B2 (en) *	2004-03-26	2007-08-07	Methylgene Inc.	Inhibitors of histone deacetylase
WO2005094370A2 (en)	2004-03-29	2005-10-13	The General Hospital Corporation	Oligonucleotide complex compositions and methods of use as gene alteration tools
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US20090048192A1 (en) *	2004-06-03	2009-02-19	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
JP4942646B2 (ja)	2004-06-15	2012-05-30	イデラファーマシューティカルズインコーポレイテッド	免疫賦活オリゴヌクレオチドマルチマー
US7498425B2 (en) *	2004-06-15	2009-03-03	Idera Pharmaceuticals, Inc.	Immunostimulatory oligonucleotide multimers
US7785843B2 (en) *	2004-06-23	2010-08-31	Sequenom, Inc.	Target-specific compomers and methods of use
EP2933332A1 (de)	2004-06-28	2015-10-21	The University Of Western Australia	Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon
USRE48960E1 (en)	2004-06-28	2022-03-08	The University Of Western Australia	Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8680062B2 (en)	2004-07-06	2014-03-25	Deliversir Ltd.	System for delivering therapeutic agents into living cells and cells nuclei
ES2401114T3 (es)	2004-08-10	2013-04-17	Genzyme Corporation	Modulación antisentido de la expresión de apolipoproteína B
EP1791567B1 (de)	2004-08-10	2015-07-29	Alnylam Pharmaceuticals Inc.	Chemisch modifizierte oligonucleotide
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006030442A2 (en)	2004-09-16	2006-03-23	Gamida-Cell Ltd.	Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US7919472B2 (en)	2004-09-17	2011-04-05	Isis Pharmaceuticals, Inc.	Enhanced antisense oligonucleotides
AU2005327506B2 (en)	2004-10-20	2010-07-08	Antisense Therapeutics Ltd	Antisense modulation of integrin alpha4 expression
US8003619B2 (en) *	2004-12-09	2011-08-23	Alnylam Pharmaceuticals, Inc.	Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
ZA200707490B (en)	2005-03-10	2008-12-31	Genentech Inc	Methods and compositions for modulatiing vascular integrity
US20060264415A1 (en) *	2005-04-01	2006-11-23	Methylgene Inc.	Inhibitors of histone deacetylase
CA2606270A1 (en) *	2005-04-19	2006-10-26	Massachusetts Institute Of Technology	Amphiphilic polymers and methods of use thereof
WO2007008300A2 (en)	2005-05-31	2007-01-18	ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE	Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
ATE439135T1 (de)	2005-07-01	2009-08-15	Index Pharmaceuticals Ab	Modulierung der reaktion auf steroide
AU2006266503B2 (en)	2005-07-01	2011-12-08	Index Pharmaceuticals Ab	Immunostimulatory method
US20070026012A1 (en)	2005-08-01	2007-02-01	Cornell Research Foundation, Inc.	Compositions and methods for monitoring and altering protein folding and solubility
US8980246B2 (en)	2005-09-07	2015-03-17	Sillajen Biotherapeutics, Inc.	Oncolytic vaccinia virus cancer therapy
KR101772375B1 (ko) *	2005-09-07	2017-08-29	신라젠(주)	Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
AU2006306805A1 (en) *	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US7470674B2 (en) *	2005-11-07	2008-12-30	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2371956A3 (de)	2005-11-07	2012-01-04	Idera Pharmaceuticals	Immunostimulatorische Eigenschaften von Oligonukleotid-basierten Verbindungen mit modifizierten immunostimulatorischen Dinukleotiden
US7776834B2 (en) *	2005-11-07	2010-08-17	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
CA2630602A1 (en)	2005-11-21	2007-05-31	Isis Pharmaceuticals, Inc.	Modulation of eif4e-bp2 expression
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
MX2008008278A (es) *	2005-12-20	2008-10-01	Idera Pharmaceuticals Inc	Agonistas sinteticos novedosos de receptores tipo toll que contienen modificaciones de dinucleotido cg.
MX2008008279A (es) *	2005-12-20	2009-03-04	Idera Pharmaceuticals Inc	Actividad inmunoestimuladora de oligonucleotidos inmunoestimuladores palindromicos que contienen diferentes longitudes de segmentos palindromicos.
WO2007123579A2 (en)	2005-12-28	2007-11-01	Translational Therapeutics	Translational dysfunction based therapeutics
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
EP1991677A2 (de)	2006-01-26	2008-11-19	Isis Pharmaceuticals, Inc.	Zusammensetzungen und deren auf huntingtin gerichtete verwendungen
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
WO2007090071A2 (en)	2006-01-27	2007-08-09	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
AU2007211082B2 (en)	2006-01-27	2012-09-27	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
CN101466670B (zh)	2006-04-07	2013-04-17	梅特希尔基因公司	组蛋白脱乙酰酶抑制剂
JP2009536222A (ja)	2006-05-05	2009-10-08	アイシスファーマシューティカルズ，インコーポレーテッド	Ｐｃｓｋ９の発現を調節するための化合物および方法
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) *	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
US8198253B2 (en)	2006-07-19	2012-06-12	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to HBXIP
ES2911034T3 (es)	2006-08-08	2022-05-17	Univ Bonn Rheinische Friedrich Wilhelms	Estructura y uso de oligonucleótidos 5' fosfato
EP1920775B1 (de)	2006-10-10	2012-12-19	Gunther Prof. Dr. Hartmann	5' Triphosphat -oligonukleotid induziert eine antivirale Reaktion
CN102886052B (zh)	2006-09-14	2014-07-30	迈德詹尼克斯医疗以色列有限公司	长效药物制剂
US8454948B2 (en)	2006-09-14	2013-06-04	Medgenics Medical Israel Ltd.	Long lasting drug formulations
WO2009016433A2 (en)	2006-09-15	2009-02-05	Ottawa Health Research Institute	Oncolytic rhabdovirus
CA2666968A1 (en)	2006-10-20	2008-10-30	Arizona Board Of Regents For And On Behalf Of Arizona State University	Modified cyanobacteria
CN105481788A (zh)	2006-10-28	2016-04-13	梅特希尔基因公司	组蛋白脱乙酰酶抑制剂
US7645578B2 (en) *	2006-10-31	2010-01-12	Agilent Technologies, Inc.	Cleavage of RNA at redundant sites
MX2009006542A (es)	2006-12-19	2009-06-30	Methylgene Inc	Inhibidores de histona desacetilasa y sus profarmacos.
EP1935428A1 (de) *	2006-12-22	2008-06-25	Antisense Pharma GmbH	Oligonukleotid-Polymer Konjugate
EP2114981B1 (de)	2007-01-29	2013-05-08	Isis Pharmaceuticals, Inc.	Verbindungen und Methoden zur Modulation der Proteinexpression
WO2009045469A2 (en)	2007-10-02	2009-04-09	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
EP2121987B1 (de)	2007-02-09	2012-06-13	Northwestern University	Partikel zur erkennung intrazellulärer ziele
US8030344B2 (en) *	2007-03-13	2011-10-04	Methylgene Inc.	Inhibitors of histone deacetylase
US9556210B2 (en)	2007-04-23	2017-01-31	Sabag-Rfa Ltd.	System for delivering therapeutic agents into living cells and cells nuclei
US9156865B2 (en)	2007-04-23	2015-10-13	Deliversir Ltd	System for delivering therapeutic agents into living cells and cells nuclei
EP2144633B1 (de) *	2007-04-23	2014-07-16	Deliversir Ltd	System zur Abgabe von therapeutischen Mitteln in lebenden Zellen und Zellkernen
EP2160464B1 (de)	2007-05-30	2014-05-21	Northwestern University	Nukleinsäure-funktionalisierte nanopartikel für therapeutische anwendungen
CA2688321A1 (en)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) *	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
KR101654007B1 (ko)	2007-08-15	2016-09-05	아이오니스 파마수티컬즈, 인코포레이티드	테트라하이드로피란 핵산 유사체
US7951785B2 (en)	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
US20100280098A1 (en) *	2007-10-05	2010-11-04	Juliano Rudolph L	Receptor targeted oligonucleotides
WO2009064920A2 (en)	2007-11-13	2009-05-22	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating protein expression
US8916531B2 (en)	2007-11-20	2014-12-23	Isis Pharmaceuticals, Inc.	Modulation of CD40 expression
WO2009067647A1 (en) *	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009073809A2 (en)	2007-12-04	2009-06-11	Alnylam Pharmaceuticals, Inc.	Carbohydrate conjugates as delivery agents for oligonucleotides
WO2009100320A2 (en) *	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
WO2009117589A1 (en) *	2008-03-21	2009-09-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
EP2274423A2 (de)	2008-04-04	2011-01-19	Isis Pharmaceuticals, Inc.	Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
US9290534B2 (en) *	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
CA2721183C (en)	2008-04-11	2019-07-16	Alnylam Pharmaceuticals, Inc.	Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2009141146A1 (en)	2008-05-21	2009-11-26	Gunther Hartmann	5' triphosphate oligonucleotide with blunt end and uses thereof
JP2011529708A (ja)	2008-08-04	2011-12-15	ユニバーシティオブマイアミ	自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子）
NZ601660A (en)	2008-08-25	2014-05-30	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2011028218A1 (en)	2009-09-02	2011-03-10	Alnylam Pharmaceuticals, Inc.	Process for triphosphate oligonucleotide synthesis
AU2009298802A1 (en)	2008-09-23	2010-04-08	Alnylam Pharmaceuticals, Inc.	Chemical modifications of monomers and oligonucleotides with cycloaddition
DK2361256T3 (da) *	2008-09-24	2013-07-01	Isis Pharmaceuticals Inc	Cyclohexenyl-nukleinsyreanaloger
DK2356129T3 (da) *	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
KR101773551B1 (ko)	2008-10-15	2017-08-31	아이오니스 파마수티컬즈, 인코포레이티드	인자 １１ 발현의 조정
EP2447274B1 (de)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomerverbindungen und Verfahren
US20120059045A1 (en)	2008-10-24	2012-03-08	Isis Pharmaceuticals, Inc.	Methods of using oligomeric compounds comprising 2'-substituted nucleosides
BR122020021379B1 (pt)	2008-10-24	2021-05-11	Sarepta Therapeutics, Inc.	oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
CN111808084A (zh)	2008-11-10	2020-10-23	阿布特斯生物制药公司	用于递送治疗剂的新型脂质和组合物
EP2365803B1 (de)	2008-11-24	2017-11-01	Northwestern University	Polyvalente rna-nanoteilchen-zusammensetzungen
US20110237649A1 (en)	2008-12-04	2011-09-29	Opko Curna, Llc	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
US20110294870A1 (en)	2008-12-04	2011-12-01	Opko Curna, Llc	Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
ES2629630T3 (es)	2008-12-04	2017-08-11	Curna, Inc.	Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
EP2376633A1 (de)	2008-12-17	2011-10-19	AVI BioPharma, Inc.	Antisense-zusammensetzungen und verfahren zur modulation von kontaktüberempfindlichkeit oder kontaktdermatitis
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
ES2762610T3 (es)	2009-02-12	2020-05-25	Curna Inc	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
CN102439149B (zh)	2009-02-12	2018-01-02	库尔纳公司	通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
AU2010221419B2 (en)	2009-03-02	2015-10-01	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
WO2010102058A2 (en)	2009-03-04	2010-09-10	Curna, Inc.	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
CN102482677B (zh)	2009-03-16	2017-10-17	库尔纳公司	通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
WO2010107740A2 (en)	2009-03-17	2010-09-23	Curna, Inc.	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
EP2424987B1 (de)	2009-05-01	2017-11-15	CuRNA, Inc.	Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
CN103223177B (zh)	2009-05-06	2016-08-10	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
ES2609655T3 (es)	2009-05-06	2017-04-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
DK2432881T3 (en)	2009-05-18	2018-02-26	Curna Inc	TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
CA2762987A1 (en)	2009-05-22	2010-11-25	Joseph Collard	Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (ko)	2009-05-28	2017-02-08	큐알엔에이, 인크.	항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
KR101766408B1 (ko)	2009-06-10	2017-08-10	알닐람 파마슈티칼스 인코포레이티드	향상된 지질 조성물
US8951981B2 (en)	2009-06-16	2015-02-10	Curna, Inc.	Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
WO2010148050A2 (en)	2009-06-16	2010-12-23	Curna, Inc.	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
WO2010151671A2 (en)	2009-06-24	2010-12-29	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (de)	2009-06-26	2016-04-20	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
CN102762731B (zh)	2009-08-05	2018-06-22	库尔纳公司	通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
CA2771172C (en)	2009-08-25	2021-11-30	Opko Curna, Llc	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
EP2470656B1 (de)	2009-08-27	2015-05-06	Idera Pharmaceuticals, Inc.	Zusammensetzung zur genexpressionshemmung und ihre anwendungen
CA2772715C (en)	2009-09-02	2019-03-26	Genentech, Inc.	Mutant smoothened and methods of using the same
ES2848650T3 (es)	2009-09-14	2021-08-11	Sillajen Biotherapeutics Inc	Terapia combinada contra el cáncer con virus vaccinia oncolítico
JP5819308B2 (ja)	2009-10-22	2015-11-24	ジェネンテック，インコーポレイテッド	マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
CA2779099C (en)	2009-10-30	2021-08-10	Northwestern University	Templated nanoconjugates
TR201816523T4 (tr)	2009-11-12	2018-11-21	Univ Western Australia	Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
EP2499248B1 (de)	2009-11-13	2017-01-04	Sarepta Therapeutics, Inc.	Antivirale antisense-verbindung und verfahren zur behandlung von influenzavirusinfektion
PH12012500982A1 (en)	2009-11-30	2019-07-10	Genentech Inc	Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
EP3296398A1 (de)	2009-12-07	2018-03-21	Arbutus Biopharma Corporation	Zusammensetzungen für nukleinsäurefreisetzung
WO2011070440A2 (en)	2009-12-10	2011-06-16	Ottawa Hospital Research Institute	Oncolytic rhabdovirus
JP6025567B2 (ja)	2009-12-16	2016-11-16	カッパーアールエヌエー，インコーポレイテッド	膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
EP3494963A1 (de)	2009-12-18	2019-06-12	The University of British Columbia	Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
CN102869776B (zh)	2009-12-23	2017-06-23	库尔纳公司	通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
RU2619185C2 (ru)	2009-12-23	2017-05-12	Курна, Инк.	Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
ES2585829T3 (es)	2009-12-29	2016-10-10	Curna, Inc.	Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
EP2519633B1 (de)	2009-12-29	2017-10-25	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
CA2785832A1 (en)	2010-01-04	2011-07-07	Curna, Inc.	Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
KR101853509B1 (ko)	2010-01-06	2018-04-30	큐알엔에이, 인크.	췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
JP6027893B2 (ja)	2010-01-11	2016-11-16	カッパーアールエヌエー，インコーポレイテッド	性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
EP2529015B1 (de)	2010-01-25	2017-11-15	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit rnase h1 mittels hemmung des natürlichen antisense-transkripts gegen rnase h1
US9198972B2 (en)	2010-01-28	2015-12-01	Alnylam Pharmaceuticals, Inc.	Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011094580A2 (en)	2010-01-28	2011-08-04	Alnylam Pharmaceuticals, Inc.	Chelated copper for use in the preparation of conjugated oligonucleotides
CN102844435B (zh)	2010-02-22	2017-05-10	库尔纳公司	通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
MA34057B1 (fr)	2010-02-23	2013-03-05	Genentech Inc	Compositions et methodes pour le diagnostic et le traitement d'une tumeur
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
EP3210611B1 (de)	2010-03-12	2019-08-21	The Brigham and Women's Hospital, Inc.	Verfahren zur behandlung von gefässentzündungserkrankungen
US9068185B2 (en)	2010-03-12	2015-06-30	Sarepta Therapeutics, Inc.	Antisense modulation of nuclear hormone receptors
US9193752B2 (en)	2010-03-17	2015-11-24	Isis Pharmaceuticals, Inc.	5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US9102938B2 (en)	2010-04-01	2015-08-11	Alnylam Pharmaceuticals, Inc.	2′ and 5′ modified monomers and oligonucleotides
WO2011127337A2 (en)	2010-04-09	2011-10-13	Opko Curna Llc	Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Conformationally restricted dinucleotide monomers and oligonucleotides
CA2797093C (en)	2010-04-26	2019-10-29	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (de)	2010-04-27	2017-08-09	aTyr Pharma, Inc.	Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von isoleucyl-trna-synthetasen
EP2601204B1 (de)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modifizierte nukleoside und daraus hergestellte oligomere verbindungen
CN103097524B (zh)	2010-04-28	2016-08-03	Atyr医药公司	与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
EP2563383B1 (de)	2010-04-29	2017-03-01	Atyr Pharma, Inc.	Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
CA2797374C (en)	2010-04-29	2021-02-16	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
PL2563920T3 (pl)	2010-04-29	2017-08-31	Ionis Pharmaceuticals, Inc.	Modulacja ekspresji transtyretyny
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
AU2011248227B2 (en)	2010-05-03	2016-12-01	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103096925A (zh)	2010-05-03	2013-05-08	Atyr医药公司	与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
ES2668207T3 (es)	2010-05-03	2018-05-17	Atyr Pharma, Inc.	Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
SG185027A1 (en)	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
JP6008844B2 (ja)	2010-05-04	2016-10-19	エータイアーファーマ，インコーポレイテッド	ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103429739B (zh)	2010-05-12	2018-11-13	哥伦比亚大学纽约管理委员会	制备产生和分泌胰岛素的肠内分泌细胞的方法
CA3090304A1 (en)	2010-05-13	2011-11-17	Sarepta Therapeutics, Inc.	Antisense modulation of interleukins 17 and 23 signaling
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP2568996B1 (de)	2010-05-14	2017-10-04	aTyr Pharma, Inc.	Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
US9034598B2 (en)	2010-05-17	2015-05-19	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
US8895528B2 (en)	2010-05-26	2014-11-25	Curna, Inc.	Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
CN103096913B (zh)	2010-05-27	2017-07-18	Atyr 医药公司	与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2580228B1 (de)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
CA2802726A1 (en)	2010-06-15	2011-12-22	Medgenics Medical Israel Ltd.	Long lasting drug formulations
AU2011289831C1 (en)	2010-07-12	2017-06-15	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
JP5998131B2 (ja)	2010-07-14	2016-09-28	カッパーアールエヌエー，インコーポレイテッド	Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
WO2012016188A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
WO2012016184A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
CN103108650A (zh)	2010-08-25	2013-05-15	Atyr医药公司	与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
ES2596977T3 (es)	2010-09-02	2017-01-13	Université de Mons	Agentes útiles en el tratamiento de la distrofia muscular facioescapulohumeral
DK2625197T3 (en)	2010-10-05	2016-10-03	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
CN103210086B (zh)	2010-10-06	2017-06-09	库尔纳公司	通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
EP2625292B1 (de)	2010-10-07	2018-12-05	The General Hospital Corporation	Krebsbiomarker
KR101865433B1 (ko)	2010-10-22	2018-07-13	큐알엔에이, 인크.	알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료
KR101913232B1 (ko)	2010-10-27	2018-10-30	큐알엔에이, 인크.	인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
CA2817256A1 (en)	2010-11-12	2012-05-18	The General Hospital Corporation	Polycomb-associated non-coding rnas
CA2817960C (en)	2010-11-17	2020-06-09	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
WO2012071238A2 (en)	2010-11-23	2012-05-31	Opko Curna Llc	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
AU2012204467B2 (en)	2011-01-04	2016-08-18	Sillajen, Inc.	Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
CA2824526C (en)	2011-01-11	2020-07-07	Alnylam Pharmaceuticals, Inc.	Pegylated lipids and their use for drug delivery
EP2663323B1 (de)	2011-01-14	2017-08-16	The General Hospital Corporation	Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
EP2668200B1 (de)	2011-01-27	2017-03-15	Ramot at Tel-Aviv University Ltd.	Inhibitoren vom lycogen-synthase-kinase-3
EP2668199B1 (de)	2011-01-27	2017-09-06	Ramot at Tel Aviv University, Ltd.	Glycogensynthasekinase-3-inhibitoren
PT2670411T (pt)	2011-02-02	2019-06-18	Excaliard Pharmaceuticals Inc	Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
DK2670404T3 (en)	2011-02-02	2018-11-19	Univ Princeton	CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
US8877722B2 (en)	2011-03-25	2014-11-04	Idera Pharmaceuticals, Inc.	Compositions for inhibiting gene expression and uses thereof
EP2508530A1 (de)	2011-03-28	2012-10-10	Rheinische Friedrich-Wilhelms-Universität Bonn	Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
AU2012240656A1 (en)	2011-04-05	2013-10-24	Academisch Ziekenhuis Leiden H.O.D.N. Lumc	Compounds and methods for altering activin receptor-like kinase signalling
EP2718427B1 (de)	2011-06-08	2017-01-11	Children's Hospital of Eastern Ontario Research Institute Inc.	Zusammensetzungen zur behandlung von glioblastomen
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
KR102043422B1 (ko)	2011-06-09	2019-11-11	큐알엔에이, 인크.	프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료
US20140227293A1 (en)	2011-06-30	2014-08-14	Trustees Of Boston University	Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
US10202599B2 (en)	2011-08-11	2019-02-12	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
WO2013033230A1 (en)	2011-08-29	2013-03-07	Isis Pharmaceuticals, Inc.	Oligomer-conjugate complexes and their use
AU2012308320C1 (en)	2011-09-14	2018-08-23	Translate Bio Ma, Inc.	Multimeric oligonucleotide compounds
AU2012308302A1 (en)	2011-09-14	2014-03-20	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
EP2760463B1 (de)	2011-09-20	2018-11-21	The University of North Carolina At Chapel Hill	Regulierung der natriumkanäle durch plunc-proteine
EP3456317B1 (de)	2011-09-27	2025-09-24	Alnylam Pharmaceuticals, Inc.	Substituierte di-aliphatic pegylierte lipide
US10184151B2 (en)	2011-10-11	2019-01-22	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
EP2596806A1 (de)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Verfahren zur Vorbeugung einer Dickdarmresektion
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
HK1202581A1 (en)	2012-02-13	2015-10-02	Gamida-Cell Ltd.	Mesenchymal stem cells conditioned medium and methods of generating and using the same
CA2866819C (en)	2012-03-13	2022-01-04	James Cook University	Method for treating inflammation
HK1210211A1 (en)	2012-03-15	2016-04-15	科纳公司	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2639238A1 (de)	2012-03-15	2013-09-18	Universität Bern	Tricyclische Nukleoside und daraus hergestellte oligomere Verbindungen
CA2907072A1 (en)	2012-03-16	2013-09-19	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of dmpk
EP2831232A4 (de)	2012-03-30	2015-11-04	Univ Washington	Verfahren zur modulation der tau-expression zur verringerung von anfällen und modifizierung eines neurodegenerativen syndroms
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
CN104704122A (zh)	2012-04-20	2015-06-10	艾珀特玛治疗公司	产热的miRNA调节剂
WO2013163628A2 (en)	2012-04-27	2013-10-31	Duke University	Genetic correction of mutated genes
WO2013173652A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics, Inc.	Compositions and methods for modulating gene expression
SG11201407483YA (en)	2012-05-16	2014-12-30	Rana Therapeutics Inc	Compositions and methods for modulating smn gene family expression
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
WO2014022852A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
CN104736551B (zh)	2012-08-15	2017-07-28	Ionis制药公司	使用改进的封端方案制备寡聚化合物的方法
HUE054260T2 (hu)	2012-09-06	2021-08-30	Univ Chicago	Antiszensz polinukleotidok exon-ugrás indukálására és eljárások disztrófiák kezelésére
EP2712870A1 (de)	2012-09-27	2014-04-02	Rheinische Friedrich-Wilhelms-Universität Bonn	Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
EP2900686B1 (de)	2012-09-28	2020-06-10	The University of North Carolina At Chapel Hill	Gegen oligodendrozyten gerichtete aav-vektoren
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
AU2013336237A1 (en)	2012-10-22	2015-06-11	Sabag-Rfa Ltd	A system for delivering therapeutic agents into living cells and cells nuclei
HK1216902A1 (zh)	2012-12-20	2016-12-09	Sarepta Therapeutics, Inc.	用作治疗肌肉萎缩的改进外显子跳跃组合物
JP2016513115A (ja)	2013-02-21	2016-05-12	チルドレンズホスピタルオブイースタンオンタリオリサーチインスティチュートインコーポレイテッド	ワクチン組成物
CN110218727A (zh)	2013-03-14	2019-09-10	萨勒普塔医疗公司	用于治疗肌营养不良的外显子跳跃组合物
CN105264091B (zh)	2013-03-14	2020-02-28	Ionis制药公司	用于调节tau表达的组合物和方法
US20140315977A1 (en)	2013-03-14	2014-10-23	Sarepta Therapeutics, Inc.	Exon skipping compositions for treating muscular dystrophy
US20140329762A1 (en)	2013-03-15	2014-11-06	Sarepta Therapeutics, Inc.	Compositions for treating muscular dystrophy
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
US9937231B2 (en)	2013-03-27	2018-04-10	The General Hospital Corporation	Methods and agents for treating Alzheimer's disease
DK2992098T3 (da)	2013-05-01	2019-06-17	Ionis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
JP6869720B2 (ja)	2013-06-13	2021-05-12	アンチセンスセラピューティクスリミテッド	併用療法
US9718859B2 (en)	2013-06-24	2017-08-01	Ramot At Tel-Aviv University Ltd.	Glycogen synthase kinase-3 inhibitors
TW202246503A (zh)	2013-07-19	2022-12-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
JP2016532456A (ja)	2013-09-18	2016-10-20	ジェームス・クック・ユニバーシティー	改変型抗炎症性タンパク質及び使用方法
CN105764523A (zh)	2013-09-18	2016-07-13	詹姆斯库克大学	抗炎蛋白及使用方法
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
WO2015061246A1 (en)	2013-10-21	2015-04-30	Isis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
DK3077510T3 (da)	2013-12-02	2020-06-08	Ionis Pharmaceuticals Inc	Antisense-forbindelser og anvendelser deraf
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
EP2883883A1 (de)	2013-12-16	2015-06-17	Cardio3 Biosciences S.A.	Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
US9636298B2 (en)	2014-01-17	2017-05-02	Methylgene Inc.	Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
WO2015117010A2 (en)	2014-01-31	2015-08-06	Temple University Of The Commonwealth System Of Higher Education	Bag3 as a target for therapy of heart failure
ES2694857T3 (es)	2014-02-04	2018-12-27	Genentech, Inc.	Smoothened mutante y métodos de uso de la misma
EP3119789B1 (de)	2014-03-17	2020-04-22	Ionis Pharmaceuticals, Inc.	Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
EP3119888B1 (de)	2014-03-19	2021-07-28	Ionis Pharmaceuticals, Inc.	Zusammensetzungen zur modulierung der ataxin-2-expression
US10006027B2 (en)	2014-03-19	2018-06-26	Ionis Pharmaceuticals, Inc.	Methods for modulating Ataxin 2 expression
HUE050704T2 (hu)	2014-04-01	2020-12-28	Biogen Ma Inc	Összetételek a SOD-1 expressziójának modulálására
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168172A1 (en)	2014-04-28	2015-11-05	Isis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
BR112016022742B1 (pt)	2014-05-01	2022-06-14	Ionis Pharmaceuticals, Inc	Composto químico, composição compreendendo o composto e uso dos mesmos
EA036496B1 (ru)	2014-05-01	2020-11-17	Ионис Фармасьютикалз, Инк.	Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
US9382540B2 (en)	2014-05-01	2016-07-05	Isis Pharmaceuticals, Inc	Compositions and methods for modulating angiopoietin-like 3 expression
TR201908550T4 (tr)	2014-06-04	2019-07-22	Exicure Inc	Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
KR102524543B1 (ko)	2014-06-10	2023-04-20	에라스무스 유니버시티 메디컬 센터 로테르담	폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드
EP3161159B1 (de)	2014-06-25	2020-08-05	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
US10487314B2 (en)	2014-06-26	2019-11-26	The Trustees Of Columbia University In The City Of New York	Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US10436802B2 (en)	2014-09-12	2019-10-08	Biogen Ma Inc.	Methods for treating spinal muscular atrophy
EP3194581A4 (de)	2014-09-15	2018-04-25	Children's Medical Center Corporation	Verfahren und zusammensetzungen zur erhöhung der somatischen zellkerntransfer(scnt)-effizienz durch entfernung der histon h3-lysin-trimethylierung
EP3663403A1 (de)	2014-09-26	2020-06-10	University of Massachusetts	Rna-modulierende stoffe
WO2016057693A1 (en)	2014-10-10	2016-04-14	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhalation delivery of conjugated oligonucleotide
JP6991857B2 (ja)	2014-10-10	2022-01-13	イデラファーマシューティカルズインコーポレイテッド	Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
EP4344741A3 (de)	2014-11-21	2024-08-28	The University of North Carolina at Chapel Hill	Auf das zentrale nervensystem gerichtete aav-vektoren
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
MX388739B (es)	2015-02-06	2025-03-20	Univ North Carolina Chapel Hill	Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
WO2016130600A2 (en)	2015-02-09	2016-08-18	Duke University	Compositions and methods for epigenome editing
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
PT3283500T (pt)	2015-04-08	2021-01-28	Univ Chicago	Composições e métodos para corrigir distrofia muscular das cinturas tipo 2c com utilização de salto do exão
US10407678B2 (en)	2015-04-16	2019-09-10	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
WO2016179634A1 (en)	2015-05-11	2016-11-17	Murdoch University	Multiple sclerosis treatment
CN108139375A (zh)	2015-06-26	2018-06-08	贝斯以色列女执事医疗中心股份有限公司	靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
EP3314027A4 (de)	2015-06-29	2019-07-03	Caris Science, Inc.	Therapeutische oligonukleotide
US10941176B2 (en)	2015-07-28	2021-03-09	Caris Science, Inc.	Therapeutic oligonucleotides
EP4285912A3 (de)	2015-09-25	2024-07-10	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
EP4089175A1 (de)	2015-10-13	2022-11-16	Duke University	Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
EP3370734B1 (de)	2015-11-05	2023-01-04	Children's Hospital Los Angeles	Antisense-oligo zur verwendung bei der behandlung von akuter myeloischer leukämie
KR20250078597A (ko)	2015-11-06	2025-06-02	아이오니스 파마수티컬즈, 인코포레이티드	아포리포프로테인 (a) 발현 조정
AU2016355178B9 (en)	2015-11-19	2019-05-30	Massachusetts Institute Of Technology	Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
KR102787119B1 (ko)	2015-11-30	2025-03-27	듀크 유니버시티	유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
EP3389670A4 (de)	2015-12-04	2020-01-08	Ionis Pharmaceuticals, Inc.	Verfahren zur behandlung von brustkrebs
WO2017099579A1 (en)	2015-12-07	2017-06-15	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
PH12018501207B1 (en)	2015-12-21	2024-02-23	Novartis Ag	Compositions and methods for decreasing tau expression
AU2016381174A1 (en)	2015-12-31	2018-05-31	Ionis Pharmaceuticals, Inc.	Methods for reducing Ataxin-2 expression
CA3006599A1 (en)	2016-01-05	2017-07-13	Ionis Pharmaceuticals, Inc.	Methods for reducing lrrk2 expression
KR20250071286A (ko)	2016-01-10	2025-05-21	네오티엑스 테라퓨틱스 엘티디.	면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
EP3411396A1 (de)	2016-02-04	2018-12-12	Curis, Inc.	Smoothened-mutant und verfahren zur verwendung davon
JP7033072B2 (ja)	2016-02-25	2022-03-09	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	Ｓｍｏｃ２を標的化する線維症のための治療方法
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
EP3429690A4 (de)	2016-03-16	2019-10-23	Ionis Pharmaceuticals, Inc.	Verfahren zur modulation von keap1
US10731166B2 (en)	2016-03-18	2020-08-04	Caris Science, Inc.	Oligonucleotide probes and uses thereof
US20190127713A1 (en)	2016-04-13	2019-05-02	Duke University	Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2017187426A1 (en)	2016-04-29	2017-11-02	Aptamir Therapeutics, Inc.	Inhibition of mir-22 mirna by apt-110
WO2017205686A1 (en)	2016-05-25	2017-11-30	Caris Science, Inc.	Oligonucleotide probes and uses thereof
AU2017286811A1 (en)	2016-06-17	2018-11-22	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
WO2018013525A1 (en)	2016-07-11	2018-01-18	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
JP7490211B2 (ja)	2016-07-19	2024-05-27	デュークユニバーシティ	Ｃｐｆ１に基づくゲノム編集の治療適用
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
HUE065170T2 (hu)	2016-09-29	2024-05-28	Biogen Ma Inc	Vegyületek és módszerek a TAU expresszió csökkentésére
US11400161B2 (en)	2016-10-06	2022-08-02	Ionis Pharmaceuticals, Inc.	Method of conjugating oligomeric compounds
US11459568B2 (en)	2016-10-31	2022-10-04	University Of Massachusetts	Targeting microRNA-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
WO2018102745A1 (en)	2016-12-02	2018-06-07	Cold Spring Harbor Laboratory	Modulation of lnc05 expression
WO2018141027A1 (en)	2017-02-03	2018-08-09	The University Of Western Australia	Novel treatment for neat1 associated disease
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
EP3609521A4 (de)	2017-04-14	2021-06-16	University of Massachusetts	Targeting von zelltropismus-rezeptoren zur hemmung von infektionen durch das cytomegalovirus
US20200033347A1 (en)	2017-04-18	2020-01-30	Universite Libre De Bruxelles	Biomarkers And Targets For Proliferative Diseases
CA3060514A1 (en)	2017-04-20	2018-10-25	Atyr Pharma, Inc.	Compositions and methods for treating lung inflammation
US12208140B2 (en)	2017-04-21	2025-01-28	The Broad Institute, Inc.	Targeted delivery to beta cells
GB201707503D0 (en)	2017-05-10	2017-06-21	Index Pharmaceuticals Ab	New Therapy 3
GB201707501D0 (en)	2017-05-10	2017-06-21	Index Pharmaceuticals Ab	New therapy 2
EP3665304A4 (de)	2017-08-11	2021-04-28	Agency for Science, Technology and Research	Verfahren zum screening von spleissvarianten oder ereignissen
WO2019036613A1 (en)	2017-08-18	2019-02-21	Ionis Pharmaceuticals, Inc.	MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
US11999953B2 (en)	2017-09-13	2024-06-04	The Children's Medical Center Corporation	Compositions and methods for treating transposon associated diseases
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US11459564B2 (en)	2017-12-21	2022-10-04	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
EP3728281A1 (de)	2017-12-21	2020-10-28	Alnylam Pharmaceuticals Inc.	Chiral angereicherte doppelsträngige rna-wirkstoffe
WO2019140102A1 (en)	2018-01-10	2019-07-18	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
AU2019206731A1 (en)	2018-01-15	2020-07-30	Ionis Pharmaceuticals, Inc.	Modulators of DNM2 expression
EP3740580A4 (de)	2018-01-19	2021-10-20	Duke University	Genom-engineering mit crispr-cas-systemen bei eukaryonten
US11732260B2 (en)	2018-03-02	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-β precursor protein
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
WO2019183440A1 (en)	2018-03-22	2019-09-26	Ionis Pharmaceuticals, Inc.	Methods for modulating fmr1 expression
WO2019186514A2 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
JP7522038B2 (ja)	2018-04-06	2024-07-24	ザチルドレンズメディカルセンターコーポレーション	体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
SG11202008660TA (en)	2018-04-11	2020-10-29	Ionis Pharmaceuticals Inc	Modulators of ezh2 expression
GB201807312D0 (en)	2018-05-03	2018-06-20	Index Pharmaceuticals Ab	Formulation
EP4663758A3 (de)	2018-05-09	2026-04-29	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur reduzierung der atxn3-expression
CU20200082A7 (es)	2018-05-09	2021-06-08	Ionis Pharmaceuticals Inc	Compuestos y métodos para la reducción de la expresión de fxi
US12582702B2 (en)	2018-05-11	2026-03-24	University Of Massachusetts	Methods for improving leptin sensitivity for the treatment of obesity and diabetes
US11786611B2 (en)	2018-05-14	2023-10-17	Murdoch University	Methods for treating VEGF-related conditions
AU2019287468B2 (en)	2018-06-12	2024-10-10	The University Of North Carolina At Chapel Hill	Synthetic liver-tropic adeno-associated virus capsids and uses thereof
CA3103429A1 (en)	2018-06-14	2019-12-19	Don W. Cleveland	Compounds and methods for increasing stmn2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
KR20210044771A (ko)	2018-07-02	2021-04-23	압타미르 테라퓨틱스, 인코포레이티드	인간 지방세포에 대한 치료제의 표적화 전달
US12496311B2 (en)	2018-07-17	2025-12-16	Aronora, Inc.	Methods for safely reducing thrombopoietin
AR115847A1 (es)	2018-07-25	2021-03-03	Ionis Pharmaceuticals Inc	Compuestos y métodos para reducir la expresión de la atxn2
SG11202100928QA (en)	2018-08-02	2021-02-25	Dyne Therapeutics Inc	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CA3110661A1 (en)	2018-08-29	2020-03-05	University Of Massachusetts	Inhibition of protein kinases to treat friedreich ataxia
WO2020048607A1 (en)	2018-09-07	2020-03-12	Université Libre de Bruxelles	Srsf2 as rna epigenetic factor
EP3867382A4 (de)	2018-10-18	2022-09-07	Murdoch University	Antisense-therapie für ptp1b-bedingte erkrankungen
GB201818579D0 (en)	2018-11-14	2018-12-26	Index Pharmaceuticals Ab	New therapy
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
CR20210311A (es)	2018-11-15	2021-07-22	Ionis Pharmaceuticals Inc	Moduladores de la expresión de irf5
US12281305B2 (en)	2018-11-21	2025-04-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing prion expression
BR112021013369A2 (pt)	2019-01-31	2021-09-21	Ionis Pharmaceuticals, Inc.	Moduladores de expressão de yap1
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
AU2020227824B2 (en)	2019-02-27	2025-07-10	Ionis Pharmaceuticals, Inc.	Modulators of MALAT1 expression
PT3947684T (pt)	2019-03-29	2025-05-19	Ionis Pharmaceuticals Inc	Compostos e métodos para modular ube3a‑ats
JP2022533358A (ja)	2019-05-14	2022-07-22	モナシュユニバーシティ	終末糖化産物受容体ｒｎａのモジュレーター及び調節
CA3139899A1 (en)	2019-05-15	2020-11-19	Neotx Therapeutics Ltd.	Cancer treatment
JP7652713B2 (ja)	2019-05-27	2025-03-27	ビジョンファーマピーティーワイリミテッド	新規の網膜色素変性処置
WO2021021673A1 (en)	2019-07-26	2021-02-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gfap
KR20220062517A (ko)	2019-08-15	2022-05-17	아이오니스 파마수티컬즈, 인코포레이티드	결합 변형된 올리고머 화합물 및 이의 용도
GB201912191D0 (en)	2019-08-24	2019-10-09	Index Pharmaceuticals Ab	New therapy
WO2021069543A1 (en)	2019-10-08	2021-04-15	Luxembourg Institute Of Health (Lih)	Inhibitor of dj-1 for use in treating immunoaging
US12241830B2 (en)	2019-12-06	2025-03-04	Broad Institute, Inc.	Living biosensors
SG10201914033YA (en)	2019-12-31	2021-07-29	Wilmar International Ltd	Polypeptides with Lipase Activity and Uses Thereof
CN120505310A (zh)	2020-02-28	2025-08-19	Ionis制药公司	用于调节smn2的化合物和方法
CN115484978A (zh)	2020-03-05	2022-12-16	尼奥克斯医疗有限公司	使用免疫细胞治疗癌症的方法和组合物
TWI901676B (zh)	2020-05-01	2025-10-21	美商Ionis製藥公司	調節ａｔｘｎ１之化合物及方法
EP4172338A4 (de)	2020-06-29	2025-06-11	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulierung von plp1
CA3189922A1 (en)	2020-07-28	2022-02-03	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing app expression
IL300258A (en)	2020-08-07	2023-03-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating SCN2A
LT4136092T (lt)	2020-11-18	2024-09-25	Ionis Pharmaceuticals, Inc.	Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui
GB202018468D0 (en)	2020-11-24	2021-01-06	Index Pharmaceuticals Ab	New therapy
WO2022133278A2 (en)	2020-12-18	2022-06-23	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor xii
CA3202832A1 (en)	2020-12-31	2022-07-07	Romesh R. Subramanian	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
AU2022293556A1 (en)	2021-06-18	2024-01-18	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ifnar1 expression
EP4147688A1 (de)	2021-09-09	2023-03-15	InDex Pharmaceuticals AB	Klistierformulierung
US20240376473A1 (en)	2021-09-16	2024-11-14	Qmine Co., Ltd.	Antisense compound for modulating wfdc2 expression
WO2023168427A1 (en)	2022-03-03	2023-09-07	Yale University	Compositions and methods for delivering therapeutic polynucleotides for exon skipping
CN120659627A (zh)	2022-07-29	2025-09-16	瑞泽恩制药公司	用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
EP4577672A1 (de)	2022-08-26	2025-07-02	The General Hospital Corporation	Verfahren und zusammensetzungen zur prognose und behandlung von dilatierter kardiomyopathie und herzinsuffizienz
JP2025532127A (ja)	2022-09-23	2025-09-29	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｍｅｃｐ２発現を低減する化合物及び方法
EP4612184A1 (de)	2022-11-04	2025-09-10	Regeneron Pharmaceuticals, Inc.	An die calcium-spannungsabhängige kanalhilfsuntereinheit gamma 1 (cacng1) bindende proteine und cacng1-vermittelte abgabe an skelettmuskeln
KR20250116795A (ko)	2022-11-14	2025-08-01	리제너론 파마슈티칼스 인코포레이티드	별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
CR20250257A (es)	2022-12-02	2025-08-28	Shanghai Argo Biopharmaceutical Co Ltd	Análogos de ácidos nucleicos bicíclicos abásicos y compuestos oligoméricos preparados a partir de estos
EP4683674A1 (de)	2023-03-23	2026-01-28	Yale University	Zusammensetzungen und verfahren zur abgabe von antikörper-oligonukleotid-konjugaten für exon-skipping
KR20250174651A (ko)	2023-04-06	2025-12-12	상하이 아르고 바이오파마슈티칼 씨오., 엘티디.	5'-포스포네이트 변형 뉴클레오시드 유사체 및 이로부터 제조된 올리고뉴클레오티드
WO2025088117A1 (en)	2023-10-25	2025-05-01	Rheinische Friedrich-Wilhelms-Universität Bonn	Ribonucleic acid construct capable of inducing an immune response, as well as pharmaceutical composition and kit comprising same
WO2025158069A1 (en)	2024-01-25	2025-07-31	Rheinische Friedrich-Wilhelms-Universität Bonn	CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
WO2025184318A1 (en)	2024-02-28	2025-09-04	The General Hospital Corporation	Methods and compositions for prognosis and treatment of peripartum cardiomyopathy
WO2025184324A1 (en)	2024-02-28	2025-09-04	The General Hospital Corporation	Methods and compositions for prognosis and treatment of cancer therapy-related cardiac dysfunction
WO2026047025A1 (en)	2024-08-27	2026-03-05	Rheinische Friedrich-Wilhelms-Universität Bonn	Photocontrollable conjugate, pharmaceutical composition and kit comprising the same, and uses thereof
WO2026080442A2 (en)	2024-10-07	2026-04-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for treating fibrotic and inflammatory diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4661450A (en) *	1983-05-03	1987-04-28	Molecular Genetics Research And Development Limited Partnership	Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides
EP0260032B1 (de) *	1986-09-08	1994-01-26	Ajinomoto Co., Inc.	Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere
US5110802A (en) *	1987-07-14	1992-05-05	City Of Hope	Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
ATE151467T1 (de) *	1987-11-30	1997-04-15	Univ Iowa Res Found	Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5098890A (en) *	1988-11-07	1992-03-24	Temple University-Of The Commonwealth System Of Higher Education	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5176996A (en) *	1988-12-20	1993-01-05	Baylor College Of Medicine	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5149798A (en) *	1989-04-06	1992-09-22	Worcester Foundation For Experimental Biology	Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
EP0476071A4 (en) *	1989-06-05	1992-11-04	Gilead Sciences, Inc.	Exonuclease-resistant oligonucleotides and methods for preparing the same
US5220007A (en) *	1990-02-15	1993-06-15	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) *	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides

1990
- 1990-02-15 US US07/480,269 patent/US5149797A/en not_active Expired - Fee Related
1991
- 1991-02-13 DK DK91904770.4T patent/DK0515511T3/da active
- 1991-02-13 WO PCT/US1991/000968 patent/WO1991012323A1/en not_active Ceased
- 1991-02-13 EP EP91904770A patent/EP0515511B1/de not_active Expired - Lifetime
- 1991-02-13 ES ES91904770T patent/ES2090314T3/es not_active Expired - Lifetime
- 1991-02-13 AT AT91904770T patent/ATE141326T1/de not_active IP Right Cessation
- 1991-02-13 DE DE69121391T patent/DE69121391T2/de not_active Expired - Fee Related
- 1991-02-13 JP JP91505563A patent/JPH05506355A/ja active Pending
- 1991-02-13 CA CA002076037A patent/CA2076037A1/en not_active Abandoned
1993
- 1993-03-24 US US08/036,503 patent/US5366878A/en not_active Expired - Fee Related
1994
- 1994-11-18 US US08/342,302 patent/US5635377A/en not_active Expired - Fee Related
1996
- 1996-10-07 GR GR960402639T patent/GR3021278T3/el unknown

Also Published As

Publication number	Publication date
US5366878A (en)	1994-11-22
CA2076037A1 (en)	1991-08-16
JPH05506355A (ja)	1993-09-22
EP0515511B1 (de)	1996-08-14
GR3021278T3 (en)	1997-01-31
EP0515511A1 (de)	1992-12-02
DE69121391T2 (de)	1997-03-06
ES2090314T3 (es)	1996-10-16
US5149797A (en)	1992-09-22
DK0515511T3 (da)	1996-11-18
DE69121391D1 (de)	1996-09-19
US5635377A (en)	1997-06-03
WO1991012323A1 (en)	1991-08-22

Legal Events

Date	Code	Title	Description
1997-03-15	UEP	Publication of translation of european patent specification
1999-11-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE141326T1 (de)	1996-08-15	Methode zur ortsspezifischen änderung von rna und produktion von dadurch kodierten polypeptiden
ATE147436T1 (de)	1997-01-15	Menschliches cytokin, interleukin-9
ATE284966T1 (de)	2005-01-15	Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
DE69942160D1 (de)	2010-04-29	Verfahren zur Herstellung von L-Aminosäure
EP0755263A4 (de)	2005-02-09	Verbindungen und methoden zur stimulierung des megakaryozytenwachstums und ihre differenzierung
ATE333501T1 (de)	2006-08-15	Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)
DE69939901D1 (de)	2008-12-24	Verfahren und materialien zur herstellung von glucosamin
ATE75483T1 (de)	1992-05-15	Oligonukleotides heilmittel und dessen herstellungsverfahren.
DE69229126D1 (de)	1999-06-10	Verfahren zur Herstellung von Thrombin
ATE423854T1 (de)	2009-03-15	Verfahren zur markierung einer ribonukleinsäure, mit reinigung
JPS6485096A (en)	1989-03-30	Hybrid human protein c and biotechnological synthesis thereof
KR840002031A (ko)	1984-06-11	Dna, 재조합 dna, 이들을 갖는 숙주 및 폴리펩타이드를 제조하는 방법
DE3587422D1 (de)	1993-07-29	Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
DE3586773D1 (de)	1992-11-26	Verfahren zur beseitigung von n-endaminosaeureresten aus eukaryotpolypeptidanlagen und so erzeugte polypeptide.
AU7093587A (en)	1987-10-08	Virus resistant plants having antisense rna
DE59509642D1 (de)	2001-10-31	Verfahren zur modifizierung der stabilität von antikörpern
DE69333491D1 (en)	2004-05-27	Protease-resistente analoge des thrombomodulin
DE69839306D1 (de)	2008-05-08	Verfahren zur herstellung und reinigung von 9-nitro-20-camptothecin
NL960017I1 (nl)	1996-10-01	Expressie van Factor VIII-activiteit in zoogdiercellen.
ATE89318T1 (de)	1993-05-15	Verfahren zur gentechnologischengewinnung von proteinen unter verwendung gramnegativer wirtzellen.
ES2127726T3 (es)	1999-05-01	Un metodo para la preparacion de hemoglobina piridoxilada.
ATE335750T1 (de)	2006-09-15	Verfahren zur herstellung von organosilylalkylpolysulfanen
IE45285L (en)	1977-12-03	Polyribonucleotides.
ES2112289T3 (es)	1998-04-01	Procedimiento de biosintesis para la preparacion de proteinas.
AUPM772494A0 (en)	1994-09-22	Improvements in production of proteins in host cells